Immuno gen, inc. – product pipeline review – 2012


Published on

2012 | ImmunoGen, Inc. – Product Pipeline Review – 2012

  • Be the first to comment

  • Be the first to like this

Immuno gen, inc. – product pipeline review – 2012

  1. 1. announces, The Latest market research report is available inits vast collection:ImmunoGen, Inc. – Product Pipeline Review – 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s pharmaceuticals report, “ImmunoGen, Inc. - ProductPipeline Review - 2012” provides data on the ImmunoGen, Inc.’s research anddevelopment focus. The report includes information on current developmentalpipeline, complete with latest updates, and features on discontinued and dormantprojects.This report is built using data and information sourced from Global Markets Direct’sproprietary databases, ImmunoGen, Inc.’s corporate website, SEC filings, investorpresentations and featured press releases, both from ImmunoGen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.Scope- ImmunoGen, Inc. - Brief ImmunoGen, Inc. overview including business description,key information and facts, and its locations and subsidiaries.- Review of current pipeline of ImmunoGen, Inc. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development,including the combination treatment modalities, across the globe.Table of contents:
  2. 2. List of Tables 5List of Figures 6ImmunoGen, Inc. Snapshot 7ImmunoGen, Inc. Overview 7Key Information 7Key Facts 7ImmunoGen, Inc. – Research and Development Overview 8Key Therapeutic Areas 8ImmunoGen, Inc. – Pipeline Review 11Pipeline Products by Stage of Development 11Pipeline Products – Monotherapy 12Pipeline Products – Combination Treatment Modalities 13ImmunoGen, Inc. – Pipeline Products Glance 14ImmunoGen, Inc. Clinical Stage Pipeline Products 14Phase II Products/Combination Treatment Modalities 14Phase I Products/Combination Treatment Modalities 15ImmunoGen, Inc. – Early Stage Pipeline Products 16Pre-Clinical Products/Combination Treatment Modalities 16ImmunoGen, Inc. – Drug Profiles 17Cancer Program 1 17Product Description 17Mechanism of Action 17R&D Progress 17Cancer Program 2 18Product Description 18Mechanism of Action 18R&D Progress 18Cancer Program 3 19Product Description 19Mechanism of Action 19R&D Progress 19huHER3-8 20Product Description 20Mechanism of Action 20R&D Progress 20
  3. 3. IMGN529 21Product Description 21Mechanism of Action 21R&D Progress 21List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Product Pipeline Review – 2012 PipelineReview – 2012&PubId=&pagenum=1Genta Incorporated – Product Pipeline Review – 2012Geron Corporation – Product Pipeline Review – 2012Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – 2012iBio, Inc. – Product Pipeline Review – 2012ImmunoGen, Inc. – Product Pipeline Review – 2012Can-Fite BioPharma Ltd. – Product Pipeline Review – 2012Celtic Biotech, Ltd. – Product Pipeline Review – 2012Cyclacel Pharmaceuticals Inc. – Product Pipeline Review – 2012
  4. 4. Endocyte, Inc. – Product Pipeline Review – 2012Flamel Technologies S.A. – Product Pipeline Review – 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: